Proposed legislation that would allot $8.75 billion in new NIH grants over the next five years comes at a cost that’s too high in the eyes of critics. They say the bill, backed by the pharmaceutical, biotechnology and medical-device industries, would weaken Food and Drug Administration scrutiny and jeopardize patient safety. Jerry Avorn, professor of medicine at Brigham and Women’s Hospital, is quoted.
